title: [Influence of different pharmacological agents in the ex vivo proliferation of mesothelial cells obtained from the peritoneal effluent of patients treated with peritoneal dialysis].
abstract: Mesothelial cells (MC) are the first peritoneal membrane barrier in contact with dialysate. The aim of this study was to analyze the in vitro capacity of different pharmacological agents to modify the ex vivo proliferation of MC obtained from the peritoneal effluent of patients treated with peritoneal dialysis (PD).
  
  
  METHODS
  Thirty cultures of MC taken from nocturnal peritoneal effluent were performed. After identification, MC are subcultured in 24 multi-well plates, adding the different exogenous agents. Proliferative capacity and cell morphology were estimated on day 16th of culture. The agents evaluated were insulin, IGF-1, tamoxifen, labetalol, carvedilol, enalapril and losartan.
  
  
  RESULTS
  Insulin shows a dose-dependent effect on MC growth, with a limit that is stimulated by the addition of fetal bovine serum (FBS). Concentrations higher than 100 micrograms/ml, are not associated with further growth, even with cell damage. In contrast, the wide range of IGF-1 dose used did not affect to MC proliferation. Tamoxifen causes negative effects on MC growth just a very high doses, not resembling doses in clinical practice. Labetalol does not modify MC proliferation used under therapeutic calculated range. However, concentrations higher than 40 micrograms/ml showed a negative influence on growth, behaving as lethal doses that over 100 micrograms/ml. The addition of FBS attenuates this effect. These effects were very similar to that caused by carvedilol addition. Enalapril and losartan act as antiproliferative agents for MC. This effect is potentiated with angiotensin II, reaching lethal concentrations increasing the dose. In conclusion, mesothelial cell growth ex vivo taken from nocturnal peritoneal effluent on PD patients is an useful tool to explore the effects of any pharmacological agent on the biology of the cell of the peritoneum. The agents used had any influence in the proliferation capacity of mesothelial cells.
authors.affiliation: Servicio de Nefrología y Servicio de Hematología-Analítica, Hospital Universitario La Paz.
authors.forename: M A
authors.initials: MA
authors.lastname: Castro
authors.forename: M A
authors.initials: MA
authors.lastname: Bajo
authors.forename: G
authors.initials: G
authors.lastname: del Peso
authors.forename: C
authors.initials: C
authors.lastname: Larrocha
authors.forename: M J
authors.initials: MJ
authors.lastname: Castro
authors.forename: J A
authors.initials: JA
authors.lastname: Sánchez-Tomero
authors.forename: A
authors.initials: A
authors.lastname: Cirugeda
authors.forename: A
authors.initials: A
authors.lastname: Aguilera
authors.forename: V
authors.initials: V
authors.lastname: Alvarez
authors.forename: O
authors.initials: O
authors.lastname: Costero
authors.forename: F
authors.initials: F
authors.lastname: Vara
authors.forename: J L
authors.initials: JL
authors.lastname: Fernández-Chacón
authors.forename: R
authors.initials: R
authors.lastname: Selgas
mesh_terms: D001202:Ascitic Fluid / Q000166:cytology*; D002452:Cell Count; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured / Q000187:drug effects; D015314:Dialysis Solutions / Q000494:pharmacology*; D004847:Epithelial Cells / Q000166:cytology*; D006801:Humans; D010529:Peritoneal Cavity / Q000166:cytology*; D010530:Peritoneal Dialysis / Q000379:methods*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage
chemical_list: D015314:Dialysis Solutions; D004364:Pharmaceutical Preparations